Gocovri was approved in 2017 by the U.S. Food and Drug Administration (FDA) as the first drug specifically indicated for levodopa-induced dyskinesia (irregular, involuntary, uncontrolled movements). The Michael J. Fox Foundation helped moved this drug to market by supporting the creation and authentication of the Unified Dyskinesia Rating Scale, a tool that was used to measure Gocovri's impact in trials.
Gocovri works on the dopamine and glutamate brain chemical pathways. The medication is a long-acting formulation of amantadine, a drug that has been available for many years. Gocovri is a capsule that is intended to be taken once daily, at bedtime, so that drug levels are highest during the day, when dyskinesia typically is most bothersome.
In addition to easing dyskinesia, this drug also may decrease total daily "off" time (when symptoms are not well controlled because Parkinson's medications are not working optimally).
For many, the once-daily dosing may be advantageous, especially if they are on otherwise complex medication regimens.
Cons and Complications
Gocovri could cause hallucinations (seeing things that aren't there), dizziness, dry mouth, swelling of the legs and feet, constipation and falls. In people who have kidney problems, the dose may need to be decreased.